Book a Demo

Auriga® - Real Time Intelligence Report

Featuring a new company biweekly with Auriga's Real Time Intelligence Report

Pfizer Inc.

Auriga® - Real Time Intelligence Report

Company Information

Company Name Ticker As of Date
Pfizer Inc. PFE.N 13-05-2026
Sector Industry
Healthcare Pharmaceuticals - Diversified
Country Region
USA AMER

Key Risk Metrics

Period ST LT
Cumulative Score 1.36 3.53
Cumulative Score: 1.36 3.53
Credit Risk Rating: B B

Heat Map

Heat Map

Business Description

Pfizer Inc. operates as a pharmaceutical company. It offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Company Graph

Company level

Pfizer Inc. [PFE.N] has a ST cumulative score of 1.36, which represents the positive impact of recent events and is anticipated to have a favorable impact on the company in the near future.

Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026. First quarter 2026 revenues totaled $14.5 billion, an increase of $736 million, or 5%, compared to the prior-year quarter, reflecting an operational increase of $304 million, or 2%.

Pfizer Inc. announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. These settlements extend the effective U.S. patent expiry date for VYNDAMAX to June 1, 2031, subject to the outcome of other litigation.

Astellas Pharma Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for perioperative (before and after surgery) PADCEV™ (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as treatment for patients with muscle-invasive bladder cancer (MIBC).

Show More Show Less
Macro Graph

Macro Level

The annual inflation rate in the US accelerated to 3.8% in April 2026, the highest since May 2023, and compared to 3.3% in March.

The US unemployment rate held at 4.3% in April 2026, in line with market expectations.

Industry Graph

Industry Level

The Pharmaceuticals Market reached US$ 1.5 trillion in 2024, rising to US$ 1.6 trillion in 2025, and is expected to reach US$ 2.5 trillion by 2033, growing at a CAGR of 5.8% during the forecast period 2026-2033.

Europe should reconsider the recent overhaul of its pharmaceutical rules and drug prices, Washington said in a critical report on global trade practices.

Get in touch
to view the complete report

    A new company is on spotlight every 2 weeks

    Fill in your details to get notified

      All Reports

      View All Reports

      Register for Auriga's Real Time Intelligence Report
      Call us +1 408 649 3056

      Contact Us Call Us